Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila

Human Molecular Genetics

Volumn 21, Issue 9, 2012, Pages 2068-2075

  Qurashi, Abrar ^a   Liu, Huijie ^a   Ray, Laurie ^a   Nelson, David L ^b   Duan, Ranhui ^c   Jin, Peng ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CONTROLLED STUDY; DNA STRUCTURE; DROSOPHILA; ENZYME ACTIVITY; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; GENETIC SCREENING; INHIBITION KINETICS; LETHALITY; LOCOMOTION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RIBO CGG REPEAT; TREMOR;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC TESTING; HUMANS; MALE; MICE; MUTATION; NERVE DEGENERATION; PHOSPHOLIPASES A2; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84859227688     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds024     Document Type: Article

References (38)

1. Warren, S.T. and Sherman, S.L. (2001) In Scriver, C.R., Beaudet, A.L., Valle, D., Childs, B., Kinzler, K.W. and Vogelstein, B. (eds), The Metabolic & Molecular Bases of Inherited Disease. McGraw-Hill Companies, New York, Vol. I, pp. 1257-1290.
2. Sherman, S. (2002) In Hagerman, R.J. (eds), Fragile X Syndrome: Diagnosis, Treatment and Research. The Johns Hopkins University Press, Baltimore, MD, pp. 136-168.
3. Hagerman, R.J. and Hagerman, P.J. (2002) The fragile X premutation: into the phenotypic fold. Curr. Opin. Genet. Dev., 12, 278-283.
4. Hagerman, P.J. and Hagerman, R.J. (2004) The fragile-X premutation: a maturing perspective. Am. J. Hum. Genet., 74, 805-816.
5. Grigsby, J., Brega, A.G., Jacquemont, S., Loesch, D.Z., Leehey, M.A., Goodrich, G.K., Hagerman, R.J., Epstein, J., Wilson, R., Cogswell, J.B. et al. (2006) Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J. Neurol. Sci., 248, 227-233.
6. Bacalman, S., Farzin, F., Bourgeois, J.A., Cogswell, J., Goodlin-Jones, B.L., Gane, L.W., Grigsby, J., Leehey, M.A., Tassone, F. and Hagerman, R.J. (2006) Psychiatric phenotype of the fragile X-associated tremor/ ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J. Clin. Psychiatry, 67, 87-94.
7. Hessl, D., Tassone, F., Loesch, D.Z., Berry-Kravis, E., Leehey, M.A., Gane, L.W., Barbato, I., Rice, C., Gould, E., Hall, D.A. et al. (2005) Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am. J. Med. Genet. B Neuropsychiatr. Genet., 139, 115-121.
8. Jacquemont, S., Farzin, F., Hall, D., Leehey, M., Tassone, F., Gane, L., Zhang, L., Grigsby, J., Jardini, T., Lewin, F. et al. (2004) Aging in individuals with the FMR1 mutation. Am. J. Ment. Retard., 109, 154-164.
9. Greco, C.M., Berman, R.F., Martin, R.M., Tassone, F., Schwartz, P.H., Chang, A., Trapp, B.D., Iwahashi, C., Brunberg, J., Grigsby, J. et al. (2006) Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain, 129, 243-255.
10. Greco, C.M., Hagerman, R.J., Tassone, F., Chudley, A.E., Del Bigio, M.R., Jacquemont, S., Leehey, M. and Hagerman, P.J. (2002) Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain, 125, 1760-1771.
11. Jin, P., Zarnescu, D.C., Zhang, F., Pearson, C.E., Lucchesi, J.C., Moses, K. and Warren, S.T. (2003) RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron, 39, 739-747.
12. Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E. and Hagerman, P.J. (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet., 66, 6-15.
13. Willemsen, R., Hoogeveen-Westerveld, M., Reis, S., Holstege, J., Severijnen, L.A., Nieuwenhuizen, I.M., Schrier, M., van Unen, L., Tassone, F., Hoogeveen, A.T. et al. (2003) The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum. Mol. Genet., 12, 949-959.
14. Tassone, F., Iwahashi, C. and Hagerman, P.J. (2004) FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol., 1, 103-105.
15. Arocena, D.G., Iwahashi, C.K., Won, N., Beilina, A., Ludwig, A.L., Tassone, F., Schwartz, P.H. and Hagerman, P.J. (2005) Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum. Mol. Genet., 14, 3661-3671.
16. Bonini, N.M. and Fortini, M.E. (2003) Human neurodegenerative disease modeling using Drosophila. Annu. Rev. Neurosci., 26, 627-656.
17. Hirth, F. (2010) Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol. Disord. Drug Targets, 9, 504-523.
18. Lessing, D. and Bonini, N.M. (2009) Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants. Nat. Rev. Genet., 10, 359-370.
19. Pfeiffenberger, C., Lear, B.C., Keegan, K.P. and Allada, R. (2010) Locomotor activity level monitoring using the Drosophila Activity Monitoring (DAM) System. Cold Spring Harb. Protoc., doi:10.1101/pdb prot5518.
20. Norris, J.F., Ilderton, E., Yardley, H.J., Summerly, R. and Forster, S. (1984) Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br. J. Dermatol., 111 (Suppl. 27), 195-203.
21. Farooqui, A.A. and Horrocks, L.A. (2006) Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist, 12, 245-260.
22. Farooqui, A.A., Ong, W.Y. and Horrocks, L.A. (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev., 58, 591-620.
23. Adibhatla, R.M. and Hatcher, J.F. (2003) Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J. Neurosci. Res., 73, 308-315.
24. Lu, X.R., Ong, W.Y. and Halliwell, B. (2001) The phospholipase A2 inhibitor quinacrine prevents increased immunoreactivity to cytoplasmic phospholipase A2 (cPLA2) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection. Exp. Brain Res., 138, 500-508.
25. Trimble, L.A., Street, I.P., Perrier, H., Tremblay, N.M., Weech, P.K. and Bernstein, M.A. (1993) NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A2. Biochemistry, 32, 12560-12565.
26. Ogata, H., Goto, S., Fujibuchi, W. and Kanehisa, M. (1998) Computation with the KEGG pathway database. Biosystems, 47, 119-128.
27. Balsinde, J., Balboa, M.A., Insel, P.A. and Dennis, E.A. (1999) Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol., 39, 175-189.
28. Glaser, K.B., Mobilio, D., Chang, J.Y. and Senko, N. (1993) Phospholipase A2 enzymes: regulation and inhibition. Trends Pharmacol. Sci., 14, 92-98.
29. Li, Q. and Cathcart, M.K. (1997) Selective inhibition of cytosolic phospholipase A2 in activated human monocytes. Regulation of superoxide anion production and low density lipoprotein oxidation. J. Biol. Chem., 272, 2404-2411.
30. Sun, G.Y., Xu, J., Jensen, M.D. and Simonyi, A. (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid. Res., 45, 205-213.
31. Todd, P.K. and Paulson, H.L. (2010) RNA-mediated neurodegeneration in repeat expansion disorders. Ann. Neurol., 67, 291-300.
32. Zoghbi, H.Y. and Botas, J. (2002) Mouse and fly models of neurodegeneration. Trends Genet., 18, 463-471.
33. Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T.C., Liu, H., Feng, Y. and Warren, S.T. (2007) Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron, 55, 556-564.
34. Qurashi, A., Li, W., Zhou, J.Y., Peng, J. and Jin, P. (2011) Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by Fragile X premutation rCGG repeats. PLoS Genet., 7, e1002102.
35. Sofola, O.A., Jin, P., Qin, Y., Duan, R., Liu, H., de Haro, M., Nelson, D.L. and Botas, J. (2007) RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron, 55, 565-571.
36. Hagerman, R.J., Hall, D.A., Coffey, S., Leehey, M., Bourgeois, J., Gould, J., Zhang, L., Seritan, A., Berry-Kravis, E., Olichney, J. et al. (2008) Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin. Interv. Aging, 3, 251-262.
37. Segalat, L. (2007) Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem. Biol., 2, 231-236.
38. Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., Wang, X., Li, X. and Luo, C. (2010) Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J. Cell Mol. Med., 14, 215-225.